INNOVEX INTERNATIONAL, INC. (INVX): what the price assumes

boothcheck covers INNOVEX INTERNATIONAL, INC. (INVX) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/INVX

Headline

FieldValue
TickerINVX
CompanyINNOVEX INTERNATIONAL, INC.
Current price$25.69/sh
CompositionProducts 70% / Services 13% / Rental 17%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)3.8%
Operating margin (mid-cycle)21.8%
Margin compression (value-band)-18.0pp
Trailing margin (depressed year)9.1%
Multiple paid8x mid-cycle operating income

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 10.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.25σ
cohort percentile (of 222 peers)2
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value, while asset-based lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.87x4expensive
Earnings1.06x5expensive
Relative1.02x5expensive
Growth0.85x3justifies

Families that justify the price: Earnings, Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=17)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$73.540.35xyesFCF base $0.2B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.9%, 7yr projection
DCF Exit MultipleGrowth$30.360.85xyesExit EV/EBITDA: 9.2x / 12.2x / 15.2x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$22.911.12xyesP/E 22.84x (blended: static sector reference 18x + trailing (TTM) 34x), scenarios: 18.3x / 22.8x / 27.4x (bear / base = reference held flat / bull), EV/EBITDA 12x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$8.133.16xyesBV/sh $14.95, ROE (TTM) 5.0%, ke 9.3%
Two-Stage Excess ReturnAsset$5.604.59xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$23.911.07xyesRev $1.0B, growth 30% (input: historical growth; tapered), Terminal P/S: 1.5x / 1.8x / 2.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$9.002.85xyesEPS $0.75, growth 1% (input: historical EPS growth), PEG=30.06 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$4.685.49xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.06B × (1−21%) / WACC 8.9% → EPV (no growth)
Residual IncomeAsset$5.314.84xyesBV $14.95 + 5yr PV of (ROE (TTM) 5.0% − Kₑ 9.3%) × BV; BV grows 3.3%/yr
Graham NumberAsset$15.891.62xyes√(22.5 × EPS $0.75 × BVPS $14.95) — Graham's conservative floor
EV/EBITDA RelativeRelative$25.261.02xyesEBITDA $0.15B × sector EV/EBITDA 12.0x
FCF YieldEarnings$27.160.95xyesFCF $179.7M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$24.811.04xyesSBC-adj FCF $0.16B (FCF $0.18B − SBC $0.01B) capitalized at Kₑ
Ben Graham FormulaEarnings$24.201.06xyesEPS $0.75 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$35.420.73xyesRevenue $0.98B × sector P/S 2.5x
PEG Fair ValueRelative$28.130.91xyesEPS $0.75 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$8.113.17xyesEPS $0.75 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$49.6m
Net debt / NOPAT (after-tax)0.29x
Net debt / operating income (pre-tax)0.23x
Interest coverage142.6x
Share count CAGR (dilution)18.9%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 21.8%); the trailing year was depressed.

Bullet Takeaways

Bull Case

Start with the balance sheet, because for a cyclical oilfield company it is the difference between surviving a downturn and being forced to sell at the bottom. Innovex carries modest net debt of roughly $50 million against trailing operating income near $89 million, so leverage is light, under a quarter of a year's operating profit. Interest coverage runs over a hundred times. A company in a notoriously boom-and-bust industry that has kept its debt small has bought itself the one thing cyclical businesses need most: the ability to keep investing and keep its customers when the cycle turns down and weaker competitors retrench.

The 2024 merger with Dril-Quip is the value-creation engine, and it is delivering ahead of plan. The company fully realized its targeted $30 million of annualized cost synergies just five months after closing, exceeding its own target. In the most recent quarter, performance beat guidance on organic growth from new products and cross-selling across the combined global platform, and management credited disciplined cost work, including exiting the legacy Eldridge manufacturing facility ahead of schedule, for margins above 20%. The subsea portfolio inherited from Dril-Quip is where the cross-selling shows up: a broader product set sold into the same customers.

The valuation is the part that separates this from a speculative cyclical. The price is supported by the earnings-power, relative-multiple, and forward-growth methods; only the asset-based lens calls it expensive. That is a value and asset-supported profile, not a story stock riding a single assumption. The company is focused on cash flow and returns rather than chasing volume, which is the right posture for a business whose end market it cannot control. A clean balance sheet, merger synergies banked, and a price the conservative earnings methods already endorse is an unusually grounded setup for an oilfield name.

Bear Case

The macro variable with the most leverage on this thesis is the one Innovex has no say over: the oil and gas spending cycle. Innovex sells the hardware and chemicals that go into drilling and completing wells, which means its revenue is a derivative of how much its customers choose to drill, and that choice is driven by commodity prices, capital discipline, and the global macro picture. When the cycle turns, activity falls fast and pricing follows. The 10-K is blunt that industry downturns or consolidation that reduces the number of customers may require the company to "lower our prices, which would adversely affect our results". That is the core fragility: a fixed-cost manufacturing base meeting a demand line that the customer can cut overnight.

Consolidation among oil and gas producers is a slower-moving version of the same risk. Every merger between two of Innovex's customers removes a buyer and shifts negotiating power toward the survivor. The bear case is not that Innovex is poorly run, the merger execution argues otherwise, but that even a well-run supplier into a consolidating, cyclical end market faces structural pressure on pricing and volume that no amount of cost discipline fully offsets.

The other watch item is the share count, which has climbed sharply because the Dril-Quip merger was an equity deal, expanding the float by roughly 19% on a trailing basis. That dilution is the price of the platform, and the bull case has to clear it: the synergies and cross-selling have to grow per-share earnings faster than the larger share base dilutes them. The balance sheet is sound and the company has term-loan and revolver capacity available, so this is not a solvency bear. It is a cyclicality-and-dilution bear: a quality cyclical whose earnings sit closer to a favorable point in the cycle than to a trough, priced on those earnings.

Valuation

The honest way to read an oilfield-products company is to ask where in the cycle the current earnings sit, because the same business can look cheap on peak earnings and expensive on trough earnings. Innovex trades at a price the earnings-power, relative-multiple, and forward-growth methods all support, with only the asset-based lens calling it expensive. The price is not making a heroic growth bet; the inversion implies a modest forward profile rather than aggressive expansion.

That broad method agreement is the reassuring part, but it carries a caveat the cycle imposes. The current operating margin of about 9% and the merger synergies that lifted it are products of a constructive activity environment plus self-help cost cuts. The methods endorse the price on those earnings; the question the buyer underwrites is whether those earnings are sustainable through a downturn or whether they compress when drilling activity slows. Among industrial-machinery and energy-equipment peers, this is a name valued on demonstrated earnings rather than on a re-rating story, which is the right frame for a cyclical.

Solvency is the strongest leg of the stool and the reason the downside is bounded. Net debt is only about $50 million against $89 million of trailing operating income, interest coverage exceeds a hundred times, and the company has revolver and term-loan capacity in reserve. Light leverage in a cyclical industry is what lets a company keep its customers and its capital program intact when the market softens. The decisive uncertainty here is not the balance sheet and not the multiple; it is the durability of the activity level that produced today's earnings.

Catalysts

The most recent quarter, the first of 2026, came in ahead of the company's own guidance. Innovex pointed to organic growth from new product introductions and cross-selling across the combined platform, with margins above 20% helped by a favorable product mix and earlier-than-expected efficiency gains from exiting the legacy Eldridge manufacturing facility. The subsea portfolio inherited from Dril-Quip was a specific bright spot the company tied to its post-merger integration.

The defining strategic event remains the Dril-Quip merger, completed in September 2024, which created the combined Innovex International platform. The company has now fully realized its $30 million of targeted annual cost synergies, reaching the figure roughly five months after close and ahead of its initial target. With the synergies banked, the next leg of the story shifts from cost-out to whether cross-selling and new products can keep growing revenue.

The forward watch items are the cyclical inputs and the cash-return posture. Management has emphasized cash flow and returns as the priority, so the pace of buybacks or deleveraging, alongside the trajectory of drilling and completion activity among its producer customers, will determine how the platform's earnings translate into per-share value against the enlarged post-merger share count.

Peer Cohorts (Per Segment, With Filing Citations)

Innovex International (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Innovex Q1 2026 earnings call · Innovex merger update

View the full interactive INVX report on boothcheck